Effects of intranasal ()-ketamine on Veterans with co-morbid treatment-resistant depression and PTSD: A retrospective case series.

Background: ()-ketamine is a glutamatergic drug with potent and rapid acting effects for the treatment of depression. Little is known about the effectiveness of intranasal ()-ketamine for treating patients with comorbid depression and post-traumatic stress disorder (PTSD).

Methods: We performed a retrospective case series analysis of clinical outcomes in 35 Veterans with co-morbid depression and PTSD who were treated with intranasal ()-ketamine treatments at the VA San Diego Neuromodulation Clinic between Jan 2020 and March 2021.

Response to intravenous racemic ketamine after switch from intranasal (S)-ketamine on symptoms of treatment-resistant depression and post-traumatic stress disorder in Veterans: A retrospective case series.

Background: Racemic (R,S)-ketamine is a glutamatergic drug with potent and rapid acting antidepressant effects. An intranasal formulation of (S)-ketamine was recently approved by the US Food and Drug Administration (FDA) to be used in individuals with treatment-resistant depression (TRD). There are no data directly comparing outcomes on depression or other comorbidities between these two formulations of ketamine.